IL15 and neoplasm: Neither agonistic anti-CD40 nor IL-15 augmented the number of tumor-specific CD8 T cells, whereas administration of the combination of IL-15 with an agonistic anti-CD40 antibody was associated with a 10-fold increase in the number of SPAS/SCNC 9H tetramer positive anti-TRAMP-C2 tumor specific CD8 T cells (68).